NM_145207.3:c.661C>T
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_145207.3(AFG2A):c.661C>T(p.Gln221*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★). Synonymous variant affecting the same amino acid position (i.e. Q221Q) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_145207.3 stop_gained
Scores
Clinical Significance
Conservation
Publications
- microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndromeInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), G2P, Orphanet, PanelApp Australia
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| AFG2A | NM_145207.3 | c.661C>T | p.Gln221* | stop_gained | Exon 5 of 16 | ENST00000274008.5 | NP_660208.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| AFG2A | ENST00000274008.5 | c.661C>T | p.Gln221* | stop_gained | Exon 5 of 16 | 1 | NM_145207.3 | ENSP00000274008.3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Microcephaly-intellectual disability-sensorineural hearing loss-epilepsy-abnormal muscle tone syndrome Pathogenic:1
This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln221*) in the SPATA5 gene. It is expected to result in an absent or disrupted protein product. This variant has not been reported in the literature in individuals with SPATA5-related disease. Loss-of-function variants in SPATA5 are known to be pathogenic (PMID: 26299366). For these reasons, this variant has been classified as Pathogenic.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at